Cheshire, UK--(Marketwire - March 6, 2008) -

                                 Protherics PLC

                         Application for Block listing

London, UK; Brentwood, TN, US: 6 March 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for the block listing of 259,014 ordinary shares of 2p each in the Company (the "Shares") to be admitted to trading on the Official List and to trading on London Stock Exchange's main market. The Shares will be used to fulfil the Company's requirement to allot shares pursuant to the exercise of options under the terms of the Company's 2005 Long-Term Incentive Plan and 2005 Deferred Bonus Plan.

The Shares will rank equally with the existing issued ordinary shares of the Company and are expected to commence trading around 7 March 2008.

Following admission of the Shares, the Company's issued share capital will be 340,187,189 Ordinary Shares.

                                   |  Ends  |


For further information please contact:

Protherics
Nick Staples, Director of Corporate Affairs          +44 (0) 7919  480510
Julie Vickers, Company Secretary                     +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott                        +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt              +1 212 850 5600


Or visit  www.protherics.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange